Eli Lilly Management

Management criteria checks 2/4

Eli Lilly's CEO is Dave Ricks, appointed in Jan 2017, has a tenure of 7.92 years. total yearly compensation is $26.57M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth €445.30M. The average tenure of the management team and the board of directors is 6.3 years and 8.5 years respectively.

Key information

Dave Ricks

Chief executive officer

US$26.6m

Total compensation

CEO salary percentage6.1%
CEO tenure7.9yrs
CEO ownership0.07%
Management average tenure6.3yrs
Board average tenure8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Ricks's remuneration changed compared to Eli Lilly's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$8b

Jun 30 2024n/an/a

US$7b

Mar 31 2024n/an/a

US$6b

Dec 31 2023US$27mUS$2m

US$5b

Sep 30 2023n/an/a

US$5b

Jun 30 2023n/an/a

US$6b

Mar 31 2023n/an/a

US$6b

Dec 31 2022US$21mUS$2m

US$6b

Sep 30 2022n/an/a

US$6b

Jun 30 2022n/an/a

US$6b

Mar 31 2022n/an/a

US$6b

Dec 31 2021US$22mUS$2m

US$6b

Sep 30 2021n/an/a

US$6b

Jun 30 2021n/an/a

US$6b

Mar 31 2021n/an/a

US$6b

Dec 31 2020US$24mUS$1m

US$6b

Sep 30 2020n/an/a

US$6b

Jun 30 2020n/an/a

US$6b

Mar 31 2020n/an/a

US$6b

Dec 31 2019US$21mUS$1m

US$5b

Sep 30 2019n/an/a

US$4b

Jun 30 2019n/an/a

US$4b

Mar 31 2019n/an/a

US$3b

Dec 31 2018US$17mUS$1m

US$3b

Sep 30 2018n/an/a

US$372m

Jun 30 2018n/an/a

-US$166m

Mar 31 2018n/an/a

US$1b

Dec 31 2017US$16mUS$1m

-US$86m

Compensation vs Market: Dave's total compensation ($USD26.57M) is above average for companies of similar size in the Austrian market ($USD4.35M).

Compensation vs Earnings: Dave's compensation has increased by more than 20% in the past year.


CEO

Dave Ricks (56 yo)

7.9yrs

Tenure

US$26,565,732

Compensation

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...


Leadership Team

NamePositionTenureCompensationOwnership
David Ricks
Chairman7.9yrsUS$26.57m0.067%
€ 445.3m
Daniel Skovronsky
EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology6.5yrsUS$11.85m0.021%
€ 142.4m
Anat Hakim
Executive VP4.8yrsUS$7.01m0.0034%
€ 22.4m
Jacob Van Naarden
Executive VP & President of Loxono dataUS$4.89m0.0023%
€ 15.1m
Lucas Montarce
Executive VP & CFOless than a yearno data0.0012%
€ 8.1m
Donald Zakrowski
Senior VP of Finance & Chief Accounting Officer12.1yrsno data0.00080%
€ 5.3m
Diogo Rau
EVP & Chief Information and Digital Officer3.6yrsUS$5.10m0.0012%
€ 8.1m
Alonzo Weems
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer3.5yrsno data0.00088%
€ 5.8m
Eric Dozier
Executive Vice President of Human Resources & Diversity2yrsno data0.00093%
€ 6.2m
Jeffrey Simmons
Senior VP & President of Elanco Animal Health16.9yrsUS$5.38mno data
W. Moody
SVP of Global Active Pharmaceutical Ingredient8.3yrsno datano data
Anne White
EVP & President of Lilly Neuroscience6.3yrsno data0.0073%
€ 48.2m

6.3yrs

Average Tenure

54yo

Average Age

Experienced Management: LLYC's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Ricks
Chairman7.9yrsUS$26.57m0.067%
€ 445.3m
Gabrielle Greene-Sulzberger
Independent Director3.9yrsUS$335.50kno data
Sidney Taurel
Chairman Emeritus15.9yrsUS$13.06mno data
Jon Erik Fyrwald
Independent Director19.1yrsUS$344.88k0.000010%
€ 66.3k
Ralph Alvarez
Independent Director15.7yrsUS$336.00k0.000080%
€ 530.0k
William Kaelin
Independent Director12.5yrsUS$349.15kno data
Mary Hedley
Independent Director2.6yrsUS$319.00k0.000040%
€ 265.0k
Juan Luciano
Lead Independent Director8.8yrsUS$373.00kno data
Katherine Baicker
Independent Director13yrsUS$336.00kno data
Jamere Jackson
Independent Director8.2yrsUS$345.00kno data
Karen Walker
Independent Director6yrsUS$359.00kno data
Kimberly Johnson
Independent Director3.8yrsUS$316.00kno data

8.5yrs

Average Tenure

62.5yo

Average Age

Experienced Board: LLYC's board of directors are considered experienced (8.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 21:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eli Lilly and Company is covered by 63 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Alistair CampbellBerenberg